PMID- 29169997 OWN - NLM STAT- MEDLINE DCOM- 20190122 LR - 20210214 IS - 1878-4216 (Electronic) IS - 0278-5846 (Print) IS - 0278-5846 (Linking) VI - 82 DP - 2018 Mar 2 TI - PSD95: A synaptic protein implicated in schizophrenia or autism? PG - 187-194 LID - S0278-5846(17)30658-9 [pii] LID - 10.1016/j.pnpbp.2017.11.016 [doi] AB - The molecular components of the postsynaptic density (PSD) in excitatory synapses of the brain are currently being investigated as one of the major etiologies of neurodevelopmental disorders such as schizophrenia (SCZ) and autism. Postsynaptic density protein-95 (PSD-95) is a major regulator of synaptic maturation by interacting, stabilizing and trafficking N-methyl-d-aspartic acid receptors (NMDARs) and alpha-amino-3-hydroxy-5-methyl-4-isox-azoleproprionic acid receptors (AMPARs) to the postsynaptic membrane. Recently, there has been overwhelming evidence that associates PSD-95 disruption with cognitive and learning deficits observed in SCZ and autism. For instance, recent genomic and sequencing studies of psychiatric patients highlight the aberrations at the PSD of glutamatergic synapses that include PSD-95 dysfunction. In animal studies, PSD-95 deficiency shows alterations in NMDA and AMPA-receptor composition and function in specific brain regions that may contribute to phenotypes observed in neuropsychiatric pathologies. In this review, we describe the role of PSD-95 as an essential scaffolding protein during synaptogenesis and neurodevelopment. More specifically, we discuss its interactions with NMDA receptor subunits that potentially affect glutamate transmission, and the formation of silent synapses during critical time points of neurodevelopment. Furthermore, we describe how PSD-95 may alter dendritic spine morphologies, thus regulating synaptic function that influences behavioral phenotypes in SCZ versus autism. Understanding the role of PSD-95 in the neuropathologies of SCZ and autism will give an insight of the cellular and molecular attributes in the disorders, thus providing treatment options in patients affected. CI - Copyright (c) 2017 Elsevier Inc. All rights reserved. FAU - Coley, Austin A AU - Coley AA AD - Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, PA 19129, United States. FAU - Gao, Wen-Jun AU - Gao WJ AD - Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, PA 19129, United States. Electronic address: wg38@drexel.edu. LA - eng GR - F99 NS105185/NS/NINDS NIH HHS/United States GR - K00 MH124182/MH/NIMH NIH HHS/United States GR - R01 MH085666/MH/NIMH NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Review DEP - 20171121 PL - England TA - Prog Neuropsychopharmacol Biol Psychiatry JT - Progress in neuro-psychopharmacology & biological psychiatry JID - 8211617 RN - 0 (Disks Large Homolog 4 Protein) SB - IM MH - Animals MH - Autism Spectrum Disorder/*metabolism MH - Disks Large Homolog 4 Protein/*metabolism MH - Humans MH - Schizophrenia/*metabolism MH - Synapses/metabolism PMC - PMC5801047 MID - NIHMS922723 OTO - NOTNLM OT - AMPAR OT - Autism OT - Glutamate OT - NMDAR OT - Neurodevelopment OT - PSD-95 OT - Schizophrenia COIS- Disclosure of Conflicts of Interest The authors report no biomedical financial interests or potential conflicts of interest. EDAT- 2017/11/25 06:00 MHDA- 2019/01/23 06:00 PMCR- 2019/03/02 CRDT- 2017/11/25 06:00 PHST- 2017/08/11 00:00 [received] PHST- 2017/10/27 00:00 [revised] PHST- 2017/11/18 00:00 [accepted] PHST- 2017/11/25 06:00 [pubmed] PHST- 2019/01/23 06:00 [medline] PHST- 2017/11/25 06:00 [entrez] PHST- 2019/03/02 00:00 [pmc-release] AID - S0278-5846(17)30658-9 [pii] AID - 10.1016/j.pnpbp.2017.11.016 [doi] PST - ppublish SO - Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:187-194. doi: 10.1016/j.pnpbp.2017.11.016. Epub 2017 Nov 21.